Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JZP269 · 1 trial · 1 indication
Area under the concentration-time curve from time 0 to 24 hours (AUC0-24), area under the concentration time curve from time 0 to the last measurable concentration (AUC0-last), and area under the concentration-time curve from time 0 to infinity will be assessed (AUC∞).
| Arm | Type | Description |
|---|---|---|
| JZP269 | EXPERIMENTAL | Participants will receive JZP269. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a matching placebo. |
| Name | Type | Description |
|---|---|---|
| JZP269 | DRUG | Administered as described. |
| Placebo | DRUG | Administered as described. |
Participants are eligible to be included in the study only if all of the following criteria apply: 1. Is 18 to 55 years of age, inclusive, at the time of signing the informed consent. 2. Is overtly healthy as determined by medical evaluation, including medical history, physical examination, laborat...
JZP269 is an investigational small molecule being developed by Jazz Pharmaceuticals plc. It is in Phase 1 clinical development and is being studied in healthy adult volunteers. No therapeutic indication for JZP269 has been disclosed.
JZP269 is being developed by Jazz Pharmaceuticals plc, which trades on the Nasdaq under the ticker JAZZ. Jazz Pharmaceuticals is the sponsor of the clinical program evaluating JZP269.
JZP269 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program is designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants.
JZP269 is being evaluated in one clinical trial, NCT07813663, titled A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants. The trial is a Phase 1 study with an estimated enrollment of 188 participants and has a status of not yet recruiting.
The JZP269 Phase 1 trial NCT07813663 is a randomized, double-blind, placebo-controlled study in healthy male and female participants aged 18 years and older. It has an estimated enrollment of 188 participants and is currently listed as not yet recruiting.